

Clinical Pharmacy

A Newsletter of Drug and Prescribing Information

Prepared by :
Department of Clinical Pharmacy
JSS College of Pharmacy at
JSS Hospital, Mahatma Gandhi Road
Mysuru – 570004

Editors : Dr. M. Ramesh, Ms. Karin Nyfort-Hansen, Ms. Juny Sebastian and Mr. Krishna Undela

Volume 23, Number 2

May - Aug 2019

ADVERSE DRUG REACTION REPORTS : JAN -APR 2019

A total of 558 Adverse Drug Reactions (ADRs) were reported to or detected by the Department of Clinical Pharmacy during January to April 2019. The following are some of the suspected ADRs that were either reported to or detected by the Department of Clinical Pharmacy. In most of the cases there was a change in drug therapy e.g. cessation of suspected drug or reduction in dose, and/or either specific or symptomatic treatment for the suspected ADR.

DRUG(S)	REACTION
Atropine	Psychosis
Carbamazepine	Steven Johnson Syndrome
Cefoperazone + Sulbactam	Leukocytoclastic vasculitis
Cisplatin	Stridor inspiratory
Dapsone	Elevated liver enzymes
Dexamethasone	Hiccups
Gabapentin	Peeling of skin
Metformin+Glimepiride	Pruritus
Phenytoin	DRESS syndrome
Rabeprazole	Erectile dysfunction
Rifabutin	Uveitis
Risperidone	Akathisia
Tinidazole	Fixed drug eruption
Vancomycin	Redman syndrome
Zidovudine + Lamivudine + Nevirapine	Lipodystrophy

Rabeprazole induced Erectile Dysfunction

Rabeprazole induced erectile dysfunction is a rare reaction. The exact mechanism is unknown. However, literature suggests that the influence of proton pump inhibitors on serum free testosterone level was the possible mechanism. The reaction can be reversed by withdrawal of the suspected drug.

Dexamethasone induced Hiccups

Dexamethasone induced hiccups is observed frequently in cancer patients. Dexamethasone lowers the threshold for synaptic transmission in the midbrain and ultimately induces hiccups. Discontinuance of dexamethasone can relieve hiccups, however, abrupt withdrawal is not recommended. Switching to methylprednisolone causes reduction in hiccups without aggravating emesis.

Rifabutin induced Uveitis

Rifabutin induced uveitis is a rare reaction that can occur even at low doses (300 mg/day). The mechanisms include immune complex deposition in uveal tissues, immune reactions to antigens released from antibiotic-induced death of microorganisms, or an alteration of melanin's ability to scavenge free radicals. This reaction can occur in Rifabutin alone patients or combination therapy with Fluconazole and other antibiotics. The reaction can be resolved by discontinuation of the suspected drug and treating with topical corticosteroids.

We encourage you to report all suspected adverse drug reactions to Department of Clinical Pharmacy. Adverse drug reaction reporting forms are available at all nursing stations. Alternatively you may call Department of Clinical Pharmacy on 2335555 Extn. 5577 or SMS to 9035664802 (Format: ADR/IP or OP Number/ Name of the patient/ Ward)

DRUGS APPROVED BY US FDA

The following are the drugs that are approved by the US Food and Drug Administration (FDA) during the period January to April 2019.

DRUG	BRAND	INDICATION
Halobetasol Propionate and tazarotene	Uobrii	For the treatment of plaque psoriasis
PrabotulinumtoxinA-xvfs	Jenuveau	For the improvement of glabellar lines
Risankizumab-rzaa	Skyrizi	For the treatment of plaque psoriasis
Testosterone undecanoate	Jatenzo	For the treatment of male conditions associated with a deficiency or absence of endogenous testosterone
Antihemophilic factor (recombinant), glycopegylated-exei	Esperoct	For the treatment of hemophilia
Caplacizumab-yhdp	Cablivi	For the treatment of acquired thrombotic thrombocytopenic purpura
Triclabendazole	Egaten	For the treatment of fascioliasis (liver fluke infestation)
Immune Globulin Intravenous, Human – slra 10% Liquid	Asceniv	For the treatment of Primary Humoral Immunodeficiency Disease
Dolutegravir and lamivudine	Dovato	For the treatment of HIV-1 infection in adults
Certolizumabpegol	Cimzia	For the treatment of non-radiographic axial spondyloarthritis
Romosozumab-aqqg	Evenity	For the treatment of osteoporosis in postmenopausal women at high risk for fracture
Cladribine	Mavenclad	For the treatment of relapsing multiple sclerosis
Siponimod	Mayzent	For the treatment of relapsing multiple sclerosis
Solriamfetol	Sunosi	For the treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea
Sumatriptan (nasal spray)	Tosymra	For the treatment of acute migraine in adults
Romosozumab-aqqg	Evenity	For the treatment of osteoporosis in postmenopausal women at high risk for fracture
Trastuzumab and hyaluronidase-oysk	Herceptin Hylecta	For the treatment of HER2-overexpressing breast cancer
Atezolizumab	Tecentriq	For the treatment of triple negative breast cancer.
Brexanolone	Zulresso	For the treatment of postpartum depression
Erdafitinib	Balversa	For the treatment of locally advanced or metastatic urothelial carcinoma
Pembrolizumab	Keytruda	For the treatment of advanced renal cell carcinoma and stage III non-small cell lung cancer
Atezolizumab	Tecentriq	For the treatment of extensive-stage small cell lung cancer
Atezolizumab	Tecentriq	For the treatment of triple negative breast cancer
Netarsudil and latanoprost ophthalmic solution	Rocklatan	For the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Esketamine (nasal spray)	Spravato	For the treatment of treatment-resistant depression in adults
Brexanolone	Zulresso	For the treatment of postpartum depression
Acidinium bromide and formoterolfumarate	Duaklir Pressair	For the maintenance treatment of chronic obstructive pulmonary disease
Pembrolizumab	Keytruda	For the treatment of stage III non-small cell lung cancer
Sunosi	Solriamfetol	For the treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea
Atezolizumab	Tecentriq	For the treatment of extensive-stage small cell lung cancer
Certolizumabpegol	Cimzia	For the treatment of non-radiographic axial spondyloarthritis
Balversa	Erdafitinib	For the treatment of locally advanced or metastatic urothelial carcinoma
Testosterone undecanoate	Jatenzo	For the treatment of male conditions associated with a deficiency or absence of endogenous testosterone

Reference : <https://www.centerwatch.com/drug-information/fda-approved-drugs/>

DRUGS APPROVED BY CDSCO, INDIA

The following are the drugs that are approved by the Central Drugs Standard Control Organization (CDSCO) during the period January to April 2019

NAME OF THE DRUG	INDICATION
Fenspiride hydrochloride film coated extended release tablet 80 mg and Fenspiride hydrochloride bulk	Acute Rhinosinusitis Moderate persistent asthma as an add- on therapy
Bilastine tablets 20 mg and Bilastine Bulk	For symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria in adults
Iguratimod film coated tablets 25mg and Iguratimod Bulk	For the treatment of active rheumatoid arthritis symptoms
Fingolimod Capsules 0.5mg and Fingolimod hydrochloride bulk	For the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
Remogliflozin etabonate bulk and Remogliflozin etabonate film coated tablets 100 mg	Indicated in adults aged 18 years and older with type2 diabetes mellitus to improve glycemic control as:- <ul style="list-style-type: none"> • Monotherapy when diet and exercise alone do not provide adequate glyceamic control. • Add on therapy with metformin, together with diet and exercise, when these do not provide adequate glyceamic control.

Reference : https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NDM00Q==

New JAK Inhibitor for Rheumatoid Arthritis Hits Targets

Early data from FINCH 1 trial (NCT02889796) suggest that use of oral Janus kinase 1 (JAK1) inhibitor, **filgotinib** leads to significant improvement in rheumatoid arthritis (RA) patients with inadequate response to methotrexate. Filgotinib could become the third drug in its class to be approved for rheumatoid arthritis, and its effectiveness and ease of use makes it a potential monotherapy choice for RA. The other two JAK inhibitors are Baricitinib (*Olumiant*, Eli Lilly) and Tofacitinib (*Xeljanz*, Pfizer) which are currently approved by the US Food and Drug Administration and the European Medicines Agency to treat rheumatoid arthritis both target the JAK pathway to ease inflammation.

FINCH 1 Trial is a Phase III, 52-week long double blind, placebo-controlled international clinical trial. The study participants, 81.8% of whom were female, had moderate to severe rheumatoid arthritis for an average of 7 to 8 years, had

an inadequate response to at least 12 weeks of methotrexate, and had been on a stable dose of methotrexate for at least 4 weeks immediately before randomization to one of four treatment groups. Of the 1755 participants, 475 participants received filgotinib 200 mg daily, 480 received filgotinib 100 mg daily, 325 received the TNF inhibitor, adalimumab (*Humira*, AbbVie) daily, and 475 received placebo. Filgotinib acted quickly and sustained its effect through week 24. It appeared to help prevent radiographic progression of the disease and improved physical function, measured with the Health Assessment Questionnaire Disability Index at week 12. Significantly more patients in the filgotinib groups than in the placebo group achieved an improvement of at least 20% in American College of Rheumatology criteria (ACR20) at 12 weeks.

Reference : <https://www.medscape.com/viewarticle/914372>

Implementation of Malaria Vaccine

RTS,S/AS01 (RTS,S) is the world's first malaria vaccine that has been shown to provide partial protection against malaria in young children. The vaccine acts against *Plasmodium falciparum*, the most deadly malaria parasite globally and the most prevalent in Africa. The vaccine has been recommended by WHO for pilot introduction in selected areas of 3 African countries. It will be evaluated for use as a complementary malaria control tool that could be added to (and not replace) the core package of WHO-recommended preventive, diagnostic and treatment measures.

The Phase 3 trial, conducted over 5 years (from 2009 to 2014), enrolled approximately 15 000 young children and infants in 7 sub-Saharan African countries. The trial sites

within these countries represented a range of malaria transmission settings. Among children aged 517 months who received 4 doses of RTS,S, the vaccine prevented approximately 4 in 10 (39%) cases of malaria over 4 years of follow-up and about 3 in 10 (29%) cases of severe malaria,³ with significant reductions also seen in overall hospital admissions as well as in admissions due to malaria or severe anaemia. The vaccine also reduced the need for blood transfusions, which are required to treat life-threatening malaria anaemia by 29%. In the Phase 3 trial, the vaccine was generally well tolerated, with adverse reactions similar to those of other childhood vaccines.

RTS,S is the first, and to date, the only vaccine to show a protective effect against malaria among young children in a Phase 3 trial. Beginning in 2019, it will be the first malaria vaccine provided to young children through routine immunization programmes. Three sub-Saharan African countries will introduce the vaccine in selected areas as part of a large-scale pilot implementation programme.

Current estimates are that at least 360,000 children per year across the 3 pilot countries will receive the RTS,S vaccine from the health facilities where they receive their routine

childhood vaccinations. A 4-dose schedule is required, with the first dose given as soon as possible after 5 months of age followed by doses 2 and 3 at approximately monthly intervals and the fourth dose near the child's second birthday. Vaccinations began in Malawi on 23rd April 2019 and in Ghana on 30th April 2019. Kenya is expected to introduce the vaccine in the coming weeks.

Reference : <https://www.who.int/malaria/media/malaria-vaccine-implementation-qa/en/>

DEPARTMENT ACTIVITIES

Exhibit of Poison Information Centre at Suttur Jathra Exhibition - 2019

The Department of Pharmacy Practice, JSS College of Pharmacy, Mysuru exhibited a stall on Poison Information Centre (located at JSS Hospital, Mysuru) during the six-days Jathra Mahotsava held during 1st-6th February 2019 at Sri Suttur Srikshetra. Several thousands of people from in and around Mysuru and nearby districts visited the stall while witnessing the event. The objective of exhibiting a stall was to showcase the various activities carried out by the Poison Information Centre and Department of Pharmacy Practice and the Institution. The stall exhibited by JSS College of Pharmacy, Mysuru was inaugurated by Dr. B. Manjunatha, Registrar, JSS AHER and Dr. P. A. Kushalappa, Director of Academics, JSS AHER and Dr. T. M. Pramod Kumar, Principal, JSS College of Pharmacy, Mysuru on Friday, 1st February 2019 at 10 am in the presence of other delegates who graced the occasion.

During the exhibit, general public were educated on the poison information services, safe use of medicines, safety precautions to be taken while using medications in elderly population, children and also about safe storage of medications. Also, the farmers were educated on safe use of pesticides and what are the preventive/ precautionary measures to be adopted to avoid the toxicity while using pesticides for farming. The public/farmers/ villagers were




*Dr. P. A. Kushalappa, Academic Director, JSSAHER,
Dr. T. M. Pramod Kumar, Principal, JSSCP,
Dr. Manjunatha B, Registrar, JSSAHER and
Dr. M. Umesh in the exhibition Hall*

also made aware of Poison information Centre run by the Department of Clinical Pharmacy located at JSS Hospital, Mysuru and its 24X7 free services on provision of information on prevention & management of different types of poisoning cases.

The Suttur Jathra Exhibition In-charge Committee appreciated our participation and the various activities carried out in align with basic theme of Suttur Jathra-2019 for the benefit of general public and rewarded our college with a participation certificate.

Continuing Professional Development (CPD) Program

The Department of Pharmacy Practice, JSS College of Pharmacy, JSS AHER, Mysuru conducted a Continuing Professional Development (CPD) Program on 'Essential Medicines & Infectious Diseases' for Practicing Pharmacists of Mysuru City on 9th February 2019 at Seminar Hall, JSS College of Pharmacy, Mysuru.



Lectures during CPD Program

This CPD program on Essential Medicines & Infectious Diseases was conducted with an objective to advance knowledge and develop skills of the practicing pharmacist pertaining to list of the essential medicines. Mrs. R. S. Savitha, Asst. Professor, Department of Pharmacy Practice led the session on 'Essential Medicines'. At the end of the session, the participants were able to describe the list of essential medicines included in the national list of essential medicines. Dr. M. Umesh, Lecturer, Department of Pharmacy Practice led the session on establishment of medication error reporting system in community pharmacies and Mr. M. S. Srikanth, Lecturer, Department of Pharmacy Practice led the session on summer borne infectious diseases. A total of 12 practicing hospital & community pharmacists from various parts of Mysuru city attended this program. Participants expressed that they benefited from this program and provided a positive feedback on the program.

Workshop on Pharmacovigilance: Basics to Advanced

The Department of Clinical Pharmacy located at JSS Hospital, Mysuru, as a part of 'Regional Training Centre for South Zone' under Pharmacovigilance Programme of India (PvPI), Ministry of Health & Family Welfare, Govt. of India extended the technical support and expertise to Nazareth College of Pharmacy, Kerala in the conduct of a 'Workshop on Pharmacovigilance: Basics to Advanced' held on 8th & 9th February 2019. The theme of the workshop was '*Medication use without harm for enhanced patient care*'. The workshop aimed to advance the knowledge and develop skills on Pharmacovigilance amongst Pharm.D students.

The workshop was inaugurated at 9 am on 8th February 2019 by Dr. Vinutha, In-charge, Family Health Centre, Othara, Thiruvalla, Kerala who was the Chief Guest of the inaugural function. Dr. Elssy Abharam, Principal, Dr. Phillip Jacob, Professor & Head, Dept. of Pharmacy Practice, and faculty members of Nazareth College of Pharmacy were also present during the inauguration. Dr. M. Ramesh, Professor & Head, Department of Pharmacy Practice, JSS College of Pharmacy, Mysuru (JSSCPM), Mrs. Juny Sebastian & Mr. Krishna Undela, Lecturers, Department of Pharmacy Practice, JSSCPM and Dr. P. Rahul Krishna, Patient Safety



Inauguration of Workshop

Pharmacovigilance Associate, PvPI were the resource persons for the workshop. A total of 60 Pharm.D students attended the workshop.

During the feedback session, organizers appreciated the efforts rendered by the regional training centre for south zone, JSS Medical College & Hospital, Mysuru in the successful conduct of the workshop. All the participants expressed that the workshop helped them to gain good understanding and knowledge on Pharmacovigilance. Also, participants expressed their satisfaction with the topics covered and hands-on sessions conducted during the workshop.

Clinical Rotation of International Students from NUST, Muscat, Oman

As part of Memorandum of Understanding (MoU) between JSS Academy of Higher Education & Research, Mysuru and National University of Science and Technology (NUST) Muscat, Oman, NINE final year B. Pharm students from College of Pharmacy, NUST, Muscat underwent seven week-long training at Department of Clinical Pharmacy, JSS Hospital, Mysuru under student study exchange program from 11th February to 29th March 2019. The aim of this experiential training program was to expose the students to an international clinical rotation in different clinical specialty areas in order to train them on basic and advanced concepts of clinical pharmacy practice.

This training program was designed to enrich students' understanding, knowledge and skills in the area of pharmaceutical care with a focus on enhancing students' learning experience on in-patient clinical pharmacy services like General Medicine, Surgery, Pediatrics, Nephrology and HIV Specialty Clinic, Oncology Pharmacy; Ambulatory Care, Hospital Pharmacy Functions, and Drug & Poison Information Service.

During the last day, students had an opportunity to meet and interact with Dr. B. Suresh, Vice Chancellor, JSS AHER, Mysuru. During this interaction, students were keen to learn about pharmacy education, practice and career opportunities in India and abroad and the same was elaborated by Dr. B. Suresh, Vice Chancellor and President, Pharmacy Council of India. Students expressed their immense satisfaction after the discussion with Dr. B. Suresh.



NUST Students with Dr. B. Suresh, Vice Chancellor, JSS AHER, Dr. B. Manjunatha, Registrar, JSS AHER, Dr. T. M. Pramod Kumar, Principal, JSSCP, Mysuru and Dr. M. Ramesh, Professor & Head, Department of Pharmacy Practice, JSSCP, Mysuru

Fifth Asia Pacific Pharmacovigilance Training Course

Fifth Asia Pacific Pharmacovigilance Training Course was conducted at Indian Pharmacopoeia Commission (IPC), Ghaziabad by Uppsala Monitoring Centre (UMC), Sweden and Pharmacovigilance Program of India (PvPI) from 4th to 15th March 2019. The course aims at building pharmacovigilance capacities amongst healthcare professionals, providing solid practical foundations for those working in medicine safety and updates for experienced staff in the Asia Pacific region and beyond.



Faculties of Department of Clinical Pharmacy during 5th Asia Pacific Pharmacovigilance Training Course

Thirty health care professionals representing national regulatory authorities, pharmaceutical companies, academia, contract research organizations from various countries in the Asia Pacific and African region were a part of the training course. Three of the faculties of the Department of Clinical Pharmacy attended the course as recourse persons. Dr. M Ramesh, Professor & Head, delivered a lecture on Causality Assessment of Adverse Drug Reactions (ADRs) and conducted a hands-on session on causality

assessment of ADR on 6th March 2019. Ms. Juny Sebastian, Lecturer delivered a lecture on causality assessment of Adverse Events Following Immunization (AEFIs) and conducted a hands-on session on causality assessment of AEFIs on 12th March 2019. Mr. Krishna Undela, Lecturer delivered lectures on pharmacoepidemiology study designs and conducted a hands-on session on signal detection on 13th March 2019 and another session on Pharmacovigilance methods on 14th March 2019.

Series of Guest Lectures on Pharmacovigilance

Mr. Sten Olsson who is an adjunct faculty at JSS Academy of Higher Education and Research, Mysuru is one of the original staff members of the Uppsala Monitoring Centre (UMC) since 1978 and a seasoned Pharmacovigilance expert. Currently, he is the President of International Society of Pharmacovigilance (ISoP), United Kingdom. Mr. Sten Olsson visited JSS College of Pharmacy, Mysuru on 18th & 19th March 2019 to deliver series of guest lectures in Pharmacovigilance for the benefit of Pharm.D Postgraduate students of Pharmacy Practice & Pharmacology and Postgraduate Diploma in Pharmacovigilance students.

On the first day, Mr. Sten delivered lectures titled “Pharmacovigilance- Role of international drug monitoring programme”, “Information resources in Pharmacovigilance” and *Research opportunities in Pharmacovigilance on the first day*. Later, he interacted with staff of Department of Pharmacy Practice.

On the second day (19th March) of the lecture series, Mr. Sten Olsson covered topics titled “Pharmacovigilance in Public Health Programmes” and “Roles and Responsibilities of International Society of Pharmacovigilance”. At the end of the session, he introduced International Society of Pharmacovigilance (ISoP) and its functions to the students



Mr. Sten Olsson with the Administrative officer, Principal, Head and lectures of pharmacy practice department, JSSCP, Mysuru

gathering. The session was concluded with a welcome note to the upcoming ISoP yearly main event.

During the session, students had an opportunity to interact and seek clarifications and suggestions related to their research works and on guest lectures. This interactive session led to a fruitful discussion on their career prospects.

Outreach Activities

Health Screening Camp

Department of Pharmacy Practice, JSS College of Pharmacy, Mysuru, in collaboration with Indian Pharmaceutical Association (IPA), Mysuru Branch organized a Health Screening Camp on 27th March 2019 at Hulikere and Majjigepura villages of Srirangapatnataluk, Mandya District for the benefit of public. The aim of the health screening camp was to sensitize the people about the importance of regular monitoring of health and safe use of medications. During the camp, interested public were screened for blood pressure and blood glucose levels. In two venues, a total of 218 people (Hulikere: 125, Majjigepura: 93) were monitored for their blood pressure and blood glucose levels. At the time of monitoring, 37 people were found with elevated blood glucose level and 53 people were found with elevated levels of blood pressure at the time of screening. People who were identified with the elevated levels of blood pressure and blood glucose levels were advised on Non-Pharmacological management and suggested to consult physician for further diagnosis &

treatment. We thank Principal, JSS College of Pharmacy, Mysuru, NSS Officers, JSS College of Pharmacy, Mysuru & Dept. Life Sciences, JSS AHER for their support in organizing this camp. Also, we thank Wockhardt Limited, for sponsoring the Blood Glucose monitors for the conduct of health screening camp.



During Health Screening Camp

Poison Information Awareness Programme

The Department of Clinical Pharmacy, JSS College of Pharmacy, Mysuru conducted awareness program on Poison Information Centre (PIC), JSS Hospital, Mysuru and its services during the NSS special camp-2019 held during 25th-31st March 2019 at Hulikere village and Majjigepura village of Srirangapatnataluk. Awareness was created among the general public and farmers on the various activities carried out by the Poison Information Centre by displaying the posters at various strategic places including primary health care centre, schools, Gram panchayat office and public places like bus stand and also near the temples located at Majjigepura and Hulikere villages. Also, public and farmers were educated on first aid measures to be adopted in case of snakebite, safe handling of pesticides and prevention of accidental poisoning in elderly and pediatric population. Following which pamphlets, education materials on poison information services were distributed.

Also, the villagers were educated on how to avail the poison information services through different modes including use of toll free number available 24X7 to get the complete information on management of any kind of poisoning cases. The villagers and the public were also informed about the



During the Awareness Program

mobile app developed to get access to various treatment protocols and information on different first aid measures in the management of poisonous cases. A talk was delivered in a local language by Dr. Umesh M, Lecturer to educate the villagers about the services provided by poison information centre and also make the villagers understand about few first aid measures to be adopted in case of snakebite, precautions to be taken while spraying pesticides, and also about prevention of accidental poisoning in elderly and pediatric population. During the awareness program, more than five hundred general public and farmers were educated on poison information services and benefited

Inter Professional Education (IPE)

IPE on Chronic Kidney Disease

Inter Professional Education on Chronic Kidney Disease (CKD) was held on 15th April 2019 at Lecture Hall-1 at JSS Hospital, Mysore. Eighth term students of MBBS and Pharm.D interns attended the session. Eighth term students presented various aspects on CKD that included the definition, epidemiology, causes, pathophysiology, complications and treatment. The presentation was made using PowerPoint format and information was collected from various sources like textbooks and guidelines. Pharm.D student discussed about the management of various complications of CKD that included hypertension, anemia, mineral bone disorders, hyperkalemia and importance of glycaemic control.

Management of each complication based on evidences from KDIGO guidelines along with its dosing regimen, advantage of one therapy over the other, treatment algorithms, newer therapies and drugs currently under trials were discussed. Non-pharmacological management like reduction in protein intake, salt intake and lifestyle modifications were addressed during the presentation. Dr. C. S. Chethan, Associate Professor, Department of Nephrology, JSS Medical College & Hospital and Mrs. R. S. Savitha, Assistant Professor, Department of Pharmacy Practice, JSS College of Pharmacy, Mysuru facilitated the IPE session. Dr. C S Chethan provided inputs on the important causes of the condition and also highlighted the importance of good presentation skills.

IPE on Acute Renal Failure

Inter Professional Education on Acute Renal Failure (ARF) was held on 22nd April 2019 at Lecture Hall-1 at JSS Hospital, Mysore. Eighth term students of MBBS and Pharm.D interns attended the session. Eighth term students presented various



Dr. Chethan Moderating Session

aspects on ARF that included the definition, epidemiology, risk factors, etiopathogenesis, complications and treatment. The presentation was made using PowerPoint format and information was collected from various sources like textbooks and guidelines. Pharm.D student discussed about the hospital acquired induced acute kidney injury (AKI) that included risk factors, causes of hospital acquired kidney injury, strategies for prevention of AKI in hospitalized patients and treatment. Non-pharmacological management like reduction in protein intake, salt intake and lifestyle modifications were addressed during the presentation. Dr. R. Rajendra Prasad Assistant Professor, Department of General Medicine, JSS Medical College & Hospital and Mr. Srikanth M.S, Lecturer, Department of Pharmacy Practice, JSS College of Pharmacy, Mysuru facilitated the IPE session. Dr. R. Rajendra Prasad and Dr. Manoj provided inputs on the important causes of the condition and also highlighted the importance of good presentation skills.

Professional Visitors of Clinical Pharmacy Department

Dr. Manas Mandal, Associate Professor, College of Pharmacy, Roseman University of Health Sciences, USA visited Department of Clinical Pharmacy located at JSS Hospital, Mysuru on 22nd January 2019. During his visit, he was briefed about various Clinical Pharmacy services provided at JSS Hospital, Mysuru. He interacted with staff and students of Clinical Pharmacy Department and emphasized on the importance of immune disorders and he expressed his interest in collaborating with our department in potential research areas.



Dr. Mandal with Staff of the Department

Pharm.D students and two faculties from Erode College of Pharmacy, Erode, Tamil Nadu visited Department of Clinical Pharmacy located at JSS Hospital, Mysuru on 3rd April 2019. The purpose of the visit was to expose the students & Faculty to pharmaceutical care services provided by the

Department of Clinical Pharmacy, JSS Hospital, Mysuru. The students spent their forenoon to learn about the various clinical pharmacy services offered to the Health Care Professionals and patients of Practice site. During their visit, students were briefed about drug therapy review with special emphasis on identification of drug related problems and Pharmacists' intervention. Also, they were explained about Adverse Drug Reaction (ADR) reporting system, reporting of medication incidents, Adverse Events Following Immunizations (AEFIs), and patient medication counselling process with a special emphasis on ambulatory patient care & JSS MINDS Initiatives (medication information for neuropsychiatric disorders & sensitization).



Students & Faculty of Erode College of Pharmacy with Staff of Department of Clinical Pharmacy

AICTE Sponsored
National Conference on
Pharmacoepidemiology & Pharmacoecomics

Organized by
Department of Pharmacy Practice
JSS College of Pharmacy, Mysuru

In Association with
JSS AHER – ISPE Student Chapter

Date: 26th – 28th September 2019
Venue: JSS College of Pharmacy, Mysuru

Theme:
*Promoting Health Outcomes
through Pharmacoepidemiology
& Pharmacoecomics Research*

The Drug & Poison Information Service

Our Department can help you with any questions you might have on the use of medicines or the management of poisoned patients. We can also assist you with any medication related problems you face in your daily practice. The services are made available on all working days and it is provided free of cost.

We request you to avail the drug and poison information services.

We extended our services 24x7 from 8th October 2018 for the benefit of HCPs and Patients.

24x7 Mobile Number: 6363539153,
Toll free Number - 1800-425-0207,
Land line Number: 2335555, Extn - 5577
E-mail: dic.jsscp@jssuni.edu.in;
pic.jsscp@jssuni.edu.in;
Website: www.picjsscpm.jssuni.edu.in

Your suggestions are welcome. Please send your comments/suggestions to the editors at: dic.jsscp@jssuni.edu.in

To,

Book - Post

